不同剂量文拉法辛与阿戈美拉汀联合应用治疗难治性抑郁症的临床效果

doi:文拉法辛；阿戈美拉汀；难治性抑郁症；疗效

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (32 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical effect of different doses of Venlafaxine and Agomelatine in the treatment of refractory depression.Methods A total of 82 patients with refractory depression who were admitted to the Department of Affective Disorders in Kangning Hospital of Shenzhen City from April 2016 to March 2018 were selected as study subjects.The patients were divided into observation group and control group,with 41 cases in each group.Patients in both groups were treated with Agomelatine Tablets after 1 week of drug washing.On this basis,patients in the control group were treated with Venlafaxine at 75-150 mg/d,while patients in the observation group were treated with Venlafaxine at 150-300 mg/d.After 7 weeks of treatment,the efficacy and incidence of adverse reactions such as headache,palpitations,dizziness,nausea,drowsiness and constipation were compared between the two groups.Results After treatment,the total effective rate of the observation group was 92.68%,which was higher than that of the control group (65.85%),the difference was statistically significant (P＜0.05).The total incidence of adverse reactions such as headache,palpitations,dizziness,nausea,lethargy,and constipation in the observation group was 14.64%,compared with the control group (12.20%),the difference was not statistically significant (P＞0.05).Conclusion According to the patients′ treatment,the dose of Venlafaxine is controlled in the range of 150-300 mg/d during the treatment,and the dose is increased as much as possible.In combination with Agomelatine in the treatment of refractory depression,the curative effect is remarkable,and the drug risk of adverse reactions is not increased,with high therapeutic safety，which is worthy of clinical application.

Key words： Venlafaxine Agomelatine Refractory depression Efficacy

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	JI Er-ni
	ZHU Lian
	CAI Lu-yao

Cite this article:

JI Er-ni,ZHU Lian,CAI Lu-yao. Clinical effect of different doses of Venlafaxine combined with Agomelatine in the treatment of refractory depression[J]. 中国当代医药, 2020, 27(1): 70-72.

URL:

http://dangdaiyiyao.com/EN/文拉法辛；阿戈美拉汀；难治性抑郁症；疗效 OR http://dangdaiyiyao.com/EN/Y2020/V27/I1/70

[1]	廖波，李彦，高镕.阿戈美拉汀治疗抑郁障碍的应用及效果评估[J].中国生化药物杂志，2017，14（10）：125-128.
[2]	陈恳，彭红星，黄兴东.阿戈美拉汀与度洛西汀治疗抑郁症患者的疗效分析[J].中国民康医学，2016，28（12）：4-6.
[3]	王晔.阿戈美拉汀与度洛西汀治疗抑郁症的临床效果比较分析[J].中国医药指南，2017，15（34）：114-115.
[4]	邹卿，袁也丰，孙伟铭.阿戈美拉汀与SSRI、SNRI 类药物治疗抑郁症疗效与安全性的Meta 分析[J].重庆医科大学学报，2017，42（10）：1288-1292.
[5]	侯连凤.阿戈美拉汀治疗抑郁症患者的临床疗效与安全问题[J].中国民康医学，2016，28（13）：29-30.
[6]	中华医学会精神病学分会.中国精神障碍分类与诊断标准第三版（精神障碍分类）[J].中华精神科杂志，2001，34（3）：184-188.
[7]	许峰，王建民，焦宗久.不同剂量文拉法辛与阿戈美拉汀治疗难治性抑郁症的疗效分析[J].国际精神病学杂志，2017，44（1）：86-88.
[8]	马素杰，马素杰，王润泽.阿戈美拉汀治疗首发抑郁症的临床效果[J].四川精神卫生，2016，29（4）：319-322.
[9]	况雷雨，谷传正，吉峰.阿戈美拉汀与5-HT 再摄取抑制剂治疗抑郁症安全性的meta 分析[J].中华行为医学与脑科学杂志，2016，25（6）：565.
[10]	周小东，付华斌，刘知源.新型抗抑郁剂：阿戈美拉丁治疗抑郁症的有效性和耐受性[J].中国健康心理学杂志，2017，25（8）：1276-1281.
[11]	肖攀攀，宋来云，郑小泳，等.加用阿戈美拉汀治疗精神分裂症强迫症状的研究[J].中国神经精神疾病杂志，2018，44（5）：283-287.
[12]	孙润珠，陈怡环，郭力.重复经颅磁刺激联合文拉法辛对老年抑郁症疗效及认知功能的影响[J].精神医学杂志，2017，30（3）：188-190.
[13]	王卓，王化宁，陈云春.高频重复经颅磁刺激联合文拉法辛治疗抑郁症的早期疗效[J].临床精神医学杂志，2012，22（3）：188-190.
[14]	汪周兵，史家波，张长春.文拉法辛联合喹硫平、奥氮平治疗难治性抑郁症的对照研究[J].国际精神病学杂志，2016，43（1）：28-30.
[15]	邓越峰.文拉法新缓释剂治疗抑郁症的开放性研究探析[J].北方药学，2017，4（10）：146-147.